# EDGAR Filing Document

**Accession Number:** 0001817229
**File Stem:** 0001193125-25-215606
**Filing Date:** 2025-9
**Character Count:** 35375
**Document Hash:** c154a2566021fe61efbad07965d5b6d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-215606.hdr.sgml**: 20250924

**ACCESSION NUMBER**: 0001193125-25-215606

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 18

**FILED AS OF DATE**: 20250924

**DATE AS OF CHANGE**: 20250924

**EFFECTIVENESS DATE**: 20250924

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vor Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001817229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811591163
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290491
- **FILM NUMBER:** 251339292

**BUSINESS ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-655-6580

**MAIL ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**As filed with the U.S. Securities and Exchange Commission on September 24, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Vor Biopharma Inc.
**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **81-1591163** |
| **(State or other jurisdiction of**<br> **Incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **500 Boylston Street**<br> **Suite 1350**<br> **Boston, Massachusetts** | **02116** |
| **(Address of principal executive offices)** | **(Zip code)** |

---

**Amended and Restated 2021 Equity Incentive Plan** 

**2023 Inducement Plan** 

**(Full titles of the plans)** 

**Jean-Paul Kress, M.D.** 

**President and Chief Executive Officer** 

**Vor Biopharma Inc.** 

**500 Boylston Street** 

**Suite 1350** 

**Boston, Massachusetts 02116** 

**(Name and address of agent for service)** 

**(617) 655-6580** 

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**Divakar Gupta** 

**Katie Kazem** 

**Cooley LLP** 

**55 Hudson Yards** 

**New York, New York 10001-2157** 

**(212) 479-6000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

Pursuant to General Instruction E of Form S-8, this Registration Statement on Form S-8 (the "Registration Statement") is being filed for the purpose of registering an additional 8,761,334 shares of common stock, $0.0001 par value per share (the "Common Stock"), of Vor Biopharma Inc. (the "Registrant"), consisting of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 1,250,000 additional shares of Common Stock issuable pursuant to the Registrant's Amended and Restated 2021
Equity Incentive Plan (the "2021 EIP"), which increase was approved by the Registrant's stockholders at the Registrant's Special Meeting of Stockholders held on August 25, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 7,511,334 additional shares of Common Stock issuable pursuant to the Registrant's 2023 Inducement Plan (the
"Inducement Plan"), which increase was approved by the Registrant's board of directors on June 25, 2025.

On September 18, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of 1-for-20 (the "Reverse Stock Split"). The information in this Registration Statement gives effect to the Reverse Stock Split.

In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

------

**PART II** 

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF DOCUMENTS BY REFERENCE**  |

---

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The contents of the Registrant's Registration Statements on Form S-8, filed with the Commission on [February 9, 2021](http://www.sec.gov/Archives/edgar/data/1817229/000119312521034595/d62481ds8.htm) (File No. 333-252908), [March 14, 2022](http://www.sec.gov/Archives/edgar/data/1817229/000119312522074747/d326176ds8.htm) (File No. 
333-263540), [March 23, 2023](http://www.sec.gov/Archives/edgar/data/1817229/000119312523077939/d472117ds8.htm) (File No. 
270789), [August 30, 2023](http://www.sec.gov/Archives/edgar/data/1817229/000119312523224996/d542471ds8.htm) (File No. 
333-274275), [March 21, 2024](http://www.sec.gov/Archives/edgar/data/1817229/000119312524072926/d786471ds8.htm) (File No. 
333-278117) and [March 20, 2025](http://www.sec.gov/Archives/edgar/data/1817229/000119312525059324/d856075ds8.htm) (File No. 333-285971);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025042623/vor-20241231.htm) for the fiscal year ended December 31, 2024, filed with the Commission on March 20, 2025 (File No. 001-39979);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Registrant's Quarterly Reports on Form 10-Q for the quarters
ended March 31, 2025 and June 30, 2025, filed with the Commission on [May 14, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025071349/vor-20250331.htm) and [August 12, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025107276/vor-20250630.htm) , respectively (File No. 001-39979);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Registrant's Current Reports on Form 8-K filed with the
Commission on [January 8, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525003259/d861124d8k.htm) ; [February 6, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525021763/d921842d8k.htm) ; [April 3, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525072340/d932261d8k.htm) ; [April 25, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525096692/d898205d8k.htm) ; [May 8, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525115554/d924194d8k.htm) ; [May 20, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525123141/d927316d8k.htm) ; [May 23, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525125833/d95113d8k.htm) ; [June 26, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525147339/d27026d8k.htm) ; [July 10, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525157638/d933755d8k.htm) ; [July 22, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525162644/d24616d8k.htm) ; [August 27, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525189169/d24419d8k.htm) ; [August 27, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525189435/d939901d8k.htm) and [September 17, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525205553/d945826d8k.htm) (File No. 001-39979), to the
extent the information in such reports is filed and not furnished;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The information specifically incorporated by reference into the Registrant's Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 from the Registrant's Revised Definitive Proxy Statement on [Schedule 14A](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525107123/d74158ddefr14a.htm) filed with the Commission on April 30, 2025 (File No. 001-39979), to the extent the information therein is filed and not furnished; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The description of the Registrant's Common Stock, which is contained in [Exhibit 4.3](http://www.sec.gov/Archives/edgar/data/1817229/000095017025042623/vor-ex4_3.htm) to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 20, 2025 (File No. 001-39979), including any amendment or report filed for the purpose of updating such description.

All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

---

| | |
|:---|:---|
| **ITEM 5.** | **INTERESTS OF NAMED EXPERTS AND COUNSEL**  |

---

As of the date of the date hereof, GC&H Investments, LLC and GC&H Investments, a California partnership, which are entities beneficially owned by current and former partners and associates of Cooley LLP, counsel to the Registrant, beneficially hold an aggregate of 1,767 shares of the Registrant's common stock.

------

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS**  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit<br>Number** | **Description** | **Schedule<br>Form** | **File<br>Number** | **Exhibit** | **Filing Date** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Certificate of Incorporation of the Registrant.](http://www.sec.gov/Archives/edgar/data/1817229/000119312521034387/d117998dex31.htm) | 8-K | 001-39979 | 3.1 | February 9, 2021 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Certificate of Amendment of Amended and Restated Certificate of Incorporation](http://www.sec.gov/Archives/edgar/data/1817229/000119312525125833/d95113dex31.htm) | 8-K | 001-39979 | 3.1 | May 23, 2025 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant.](http://www.sec.gov/Archives/edgar/data/1817229/000119312525205553/d945826dex31.htm) | 8-K | 001-39979 | 3.1 | September 17, 2025 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.4 | [Amended and Restated Bylaws of the Registrant.](http://www.sec.gov/Archives/edgar/data/1817229/000119312521034387/d117998dex32.htm) | 8-K | 001-39979 | 3.2 | February 9, 2021 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.5\* | [Form of Common Stock Certificate of the Registrant.](d59565dex45.htm) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Cooley LLP.](d59565dex51.htm) |  |  |  |  |
| 23.1\* | [Consent of Cooley LLP (included in Exhibit 5.1).](d59565dex51.htm) |  |  |  |  |
| 23.2\* | [Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.](d59565dex232.htm) |  |  |  |  |
| 24.1\* | [Power of Attorney (included on the signature page of this registration statement).](d59565ds8.htm#sig) |  |  |  |  |
| 99.1 | [2021 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement.](http://www.sec.gov/Archives/edgar/data/1817229/000119312521023537/d942530dex106.htm) | S-1/A | 333-252175 | 10.6 | February 1, 2021 |
| 99.2 | [Amended and Restated 2021 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1817229/000119312525189169/d24419dex101.htm) | 8-K | 001-39979 | 10.1 | August 27, 2025 |
| 99.3 | [2023 Inducement Plan.](http://www.sec.gov/Archives/edgar/data/1817229/000119312523224996/d542471dex991.htm) | S-8 | 333-274275 | 99.1 | August 30, 2023 |
| 107\* | [Filing Fee Table.](d59565dexfilingfees.htm) |  |  |  |  |

---

\* Filed herewith

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on September 24, 2025.

---

| | |
|:---|:---|
| **VOR BIOPHARMA INC.** | **VOR BIOPHARMA INC.** |
| By: | /s/ Jean-Paul Kress |
|  | Jean-Paul Kress, M.D. |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS** **BY THESE** **PRESENTS**, that each person whose signature appears below constitutes and appoints Jean-Paul Kress and Sandesh Mahatme, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Jean-Paul Kress<br> Jean-Paul Kress, M.D. | President, Chief Executive Officer and Chairman of the Board<br> (*Principal Executive Officer*) | September 24, 2025 |
| /s/ Sandesh Mahatme<br> Sandesh Mahatme | Chief Financial Officer<br> (*Principal Financial Officer and Principal Accounting Officer*) | September 24, 2025 |
| /s/ Daniella Beckman<br> Daniella Beckman | Director | September 24, 2025 |
| /s/ Alexander Cumbo<br> Alexander Cumbo | Director | September 24, 2025 |
| /s/ Michel Detheux<br> Michel Detheux | Director | September 24, 2025 |
| /s/ Erez Kalir<br> Erez Kalir | Director | September 24, 2025 |
| /s/ Fouad Namouni<br> Fouad Namouni, M.D. | Director | September 24, 2025 |
| /s/ Sarah Reed<br> Sarah Reed | Director | September 24, 2025 |

---

## Exhibit 4.5

**Exhibit 4.5**![LOGO](g59565dsp008.jpg)

PO PAR VALUE $0.0001MR ADDADDADDADD 4321 A BoxDESIGNATIONSAMPLE 43004, Certificate Shares(IF Number \*\* 000000 \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* ANY) ZQ00000000 \*\*\* 000000 \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* \*\*\*\* 000000 \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Providence \*\*\*\*\* 000000 \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*RI VOR BIOPHARMA INC. \*\*\*\*\*\* 000000 \*\*\*\*\*\*\*\*\*\*\*\*\*\*INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE02940 \*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample SEE REVERSE FOR CERTAIN DEFINITIONS- THIS CERTIFIES THAT \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. 3004 Alexander David Sample MR \*\*\*\* Mr. Alexander . SAMPLE David Sample \*\*\*\* Mr. Alexander &David MRS Sample \*\*\*\* Mr.Alexander SAMPLE David Sample \*\*\*\* Mr. Alexander & David Sample \*\*\*\* CUSIP 929033 20 7 Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. AlexanderMR David Sample . \*\*\*\* SAMPLE Mr. Alexander David Sample \*\*\*\* &Mr . Alexander MRS David Sample . SAMPLE \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Alexander David Sample \*\*\*\* Mr. Sample \*\*\*\* Mr. Sample\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Sha is the owner of res\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*S hares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\* THIS CERTIFICATE IS TRANSFERABLE IN Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000 \*\*\*ZERO HUNDRED THOUSAND \*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*0000 CITIES DESIGNATED BY THE TRANSFER 00\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*00 AGENT, AVAILABLE ONLINE AT 0000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\* 000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\* ZERO HUNDRED AND ZERO\*\*\* www.computershare.com 000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\* 000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\* 000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*000000\*\*Shares\*\*\*\*FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OFVor Biopharma Inc. (hereinafter called the "Company"), transferable on the books of the Company in person or Total DTC by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares Holder represented hereby, are issued and shall be held subject to all of the provisions of the Articles of Incorporation, Number InsuranceID as amended, and the By-Laws, as amended, of the Company (copies of which are on file with the Company andCertificate of with the Transfer Agent), to all of which each holder, by acceptance hereof, assents. This Certificate is not valid Value unless countersigned and registered by the Transfer Agent and Registrar.Transaction Shares CUSIP/IDENTIFIER Numbers 1234567890/12345678901234567890/12345678901234567890/12345678901234567890/12345678901234567890/12345678901234567890/1234567890 Witness the facsimile seal of the Company and the facsimile signatures of its duly authorized officers.DATED DD-MMM-YYYYOPHAR COUNTERSIGNED AND REGISTERED:654321 B I MA12345678 I COMPUTERSHARE TRUST COMPANY, N.A. R RPORA N O O TNum/No C E C. CEO & CHAIRMAN V . TRANSFER AGENT AND REGISTRAR,654321Denom DATE. XXXXXX DEL R E 1,000,000 AWA7654321 . XXTotal 12345678901234512345600XXXXXXXXXXX By59565-001 23Sep25 01:16 Page CHIEF 8 FINANCIAL OFFICER AUTHORIZED SIGNATURE. ZQ\|CERT#\|COY\|CLS\|RGSTRY\|ACCT#\|TRANSTYPE\|RUN#\|TRANS#COMMON STOCK COMMON STOCK

------

![LOGO](g59565dsp009.jpg)

. VOR BIOPHARMA INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS, PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE ARTICLES OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS LEGAL REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE. For US purposes the following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM - as tenants in common UNIF GIFT MIN ACT -............................................ (Cust) Custodian ................................................ (Minor) TEN ENT - as tenants by the entireties under Uniform Gifts to Minors Act ........................................................ (State) JT TEN - and as joint not tenants as tenants with in right common of survivorship UNIF TRF MIN ACT -............................................ (Cust) Custodian (until age ................................) .............................under Uniform Transfers to Minors Act ................... (Minor) (State) Additional abbreviations may also be used though not in the above list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For value received, ____________________________ hereby sell, assign and transfer unto _______________________________________________________________________________________________________________________________ (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) _________________________________________________________________________________________________________________________ Shares of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint ________________________________________________________________________________________________________________________ Attorney to transfer the said stock on the books of the within-named Company with full power of substitution in the premises. Dated: ________________________________________ 20_________________ Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Signature: _________________________________________________________ Stockbrokers, Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15. Signature: _________________________________________________________ Notice: The signature to this assignment must correspond with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any change whatever. basis The IRS of certain requires shares that the or units named acquired transfer after agent January ("we") 1, report 2011 the . If cost your shares or transfer or units the shares are covered or units by using the legislation, a specific and cost you basis requested calculation to sell method, specify a then cost we basis have calculation processed method, as you then requested we have . If defaulted you did not to the need first in, additional first out (FIFO) information method about . Please cost basis consult . your tax advisor if you 59565-001 23Sep25 01:16 If you Page do not keep 9 in contact with the issuer or do not have any activity your property in your may account become for the subject time to period state specified unclaimed by property state law, laws and transferred to the appropriate state.

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g59565g0924091215378.jpg)

Katie Kazem

T: +1 703 456 8043

kkazem@cooley.com

September 24, 2025

Vor Biopharma Inc.

500 Boylston Street, Suite 1350

Boston, Massachusetts 02116

Ladies and Gentlemen:

We have acted as counsel to Vor Biopharma Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a registration statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 8,761,334 shares (the "***Shares***") of the Company's common stock, par value $0.0001 per share (the "***Common Stock***"), consisting of (i) 1,250,000 shares of Common Stock issuable pursuant to the Company's Amended and Restated 2021 Equity Incentive Plan (the "***2021 Plan***") and (ii) 7,511,334 shares of Common Stock issuable pursuant to the Company's 2023 Inducement Plan (together with the 2021 Plan, the "***Plans***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectuses, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Plans and (d) such records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

Our opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. Our opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

Cooley LLP Reston Town Center 11951 Freedom Drive 14th Floor Reston, VA 20190-5656

t: +1 703 456 8000 f: +1 703 456 8100 cooley.com

------

![LOGO](g59565g0924091215378.jpg)

Vor Biopharma Inc.

September 24, 2025

Page Two

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| Cooley LLP | Cooley LLP |
| By: | /s/ Katie Kazem |
|  | Katie Kazem |

---

Cooley LLP Reston Town Center 11951 Freedom Drive 14th Floor Reston, VA 20190-5656

t: +1 703 456 8000 f: +1 703 456 8100 cooley.com

## Exhibit 23.2

**Exhibit 23.2** 

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Amended and Restated 2021 Equity Incentive Plan and the 2023 Inducement Plan of Vor Biopharma Inc. of our report dated March 20, 2025, with respect to the consolidated financial statements of Vor Biopharma Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

September 24, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Vor Biopharma Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.0001 per share, reserved for issuance pursuant to the Amended and Restated 2021 Equity Incentive Plan | 457(a) | 1250000 | $27.74 | $34675000.00 | 0.0001531 | $5308.74 |
| 2 | Equity | Common Stock, par value $0.0001 per share, reserved for issuance pursuant to the 2023 Inducement Plan | 457(a) | 7511334 | $27.74 | $208364405.16 | 0.0001531 | $31900.59 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $243039405.16  |  | $37209.33  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $37209.33  |

---

 **Offering Note** <br>

<sup>1</sup> &nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Registrant's common stock that become issuable under the Registrant's Amended and Restated 2021 Equity Incentive Plan (the "2021 EIP") and the Registrant's 2023 Inducement Plan (the "Inducement Plan") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant's common stock, as applicable. The proposed maximum offering price per share of Common Stock is estimated solely for the purpose of calculating the proposed maximum aggregate offering price and the registration fee in accordance with Rules 457(c) and (h) under the Securities Act, based on the average of the high and low prices of the Registrant's common stock as reported in the consolidated reporting system of The Nasdaq Global Select Market on September 22, 2025, which was $27.74.

<sup>2</sup> &nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Registrant's common stock that become issuable under the Registrant's Amended and Restated 2021 Equity Incentive Plan (the "2021 EIP") and the Registrant's 2023 Inducement Plan (the "Inducement Plan") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant's common stock, as applicable. The proposed maximum offering price per share of Common Stock is estimated solely for the purpose of calculating the proposed maximum aggregate offering price and the registration fee in accordance with Rules 457(c) and (h) under the Securities Act, based on the average of the high and low prices of the Registrant's common stock as reported in the consolidated reporting system of The Nasdaq Global Select Market on September 22, 2025, which was $27.74.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---